REDWOOD CITY, Calif.,
Oct. 30, 2017 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a
specialty pharmaceutical company, today announced that it will
release third quarter financial results after market close on
Thursday, November 9th. AcelRx
management will host a conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on Thursday, November 9th to discuss the financial
results and provide an update on the company's performance.
Investors who wish to participate in the conference call may do
so by dialing (866) 361-2335 for domestic callers, (855) 669-9657
for Canadian callers or (412) 902-4204 for international callers.
Those interested in listening to the conference call live via the
Internet may do so by visiting the Investors page of the company's
website at www.acelrx.com and clicking on the webcast link on the
Investors home page.
A webcast replay will be available on the AcelRx website for 90
days following the call by visiting the Investor page of the
company's website at www.acelrx.com.
About AcelRx
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of moderate-to-severe acute
pain. AcelRx's proprietary, non-invasive sublingual formulation
technology delivers sufentanil with consistent pharmacokinetic
profiles. The company has two product candidates including
DSUVIA™ (sufentanil sublingual tablet, 30 mcg), known as
ARX-04 outside the United States,
with a proposed indication for the treatment of moderate-to-severe
acute pain in medically supervised settings, and
ZALVISO® (sufentanil sublingual tablet system, SST
system, 15 microgram) being developed as an innovatively designed
patient-controlled analgesia (PCA) system for reduction of
moderate-to-severe acute pain in medically supervised settings.
For additional information about AcelRx's clinical programs,
please visit www.acelrx.com.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to the process
and timing of anticipated future development of AcelRx's product
candidates, DSUVIA™ (sufentanil sublingual tablet, 30
mcg), known as ARX-04 outside the United
States, and ZALVISO® (sufentanil sublingual
tablet system), including U.S. Food and Drug Administration, or
FDA, review of the New Drug Application, or NDA, for DSUVIA;
evaluation of the CRL and AcelRx's plans for resubmission of the
NDA for DSUVIA with the FDA; the timing of the planned resubmission
of the ZALVISO NDA; and the Company's ability to continue its cash
management plan and maintain a solid liquidity position. These
forward-looking statements are based on AcelRx Pharmaceuticals'
current expectations and inherently involve significant risks and
uncertainties. AcelRx Pharmaceuticals' actual results and timing of
events could differ materially from those anticipated in such
forward-looking statements, and as a result of these risks and
uncertainties, which include, without limitation, risks related to
AcelRx Pharmaceuticals' DSUVIA and ARX-04 development programs,
including the EMA review of the ARX-04 MAA, and the possibility
that EMA may dispute or interpret differently clinical results
obtained from the ARX-04 Phase 2 and 3 studies; the possibility
that the FDA may dispute or interpret differently the results of
the ZALVISO development program, including the results from the
IAP312 clinical trial; the resubmission of the ZALVISO NDA to the
FDA; any delays or inability to obtain and maintain regulatory
approval of its product candidates, including DSUVIA in
the United States, ARX-04 in
Europe and ZALVISO in the United States; the uncertain clinical
development process, including adverse events; the success, cost
and timing of all development activities and clinical trials; the
accuracy of AcelRx's estimates regarding expenses, capital
requirements and the need for financing; and other risks detailed
in the "Risk Factors" and elsewhere in AcelRx's U.S. Securities and
Exchange Commission filings and reports, including its Quarterly
Report on Form 10-Q filed with the SEC on August 2, 2017. AcelRx undertakes no duty or
obligation to update any forward-looking statements contained in
this release as a result of new information, future events or
changes in its expectations.
![AcelRx logo. (PRNewsFoto/AcelRx Pharmaceuticals, Inc.) AcelRx logo. (PRNewsFoto/AcelRx Pharmaceuticals, Inc.)](https://mma.prnewswire.com/media/593534/ACELRX_PHARMACEUTICALS__INC__LOGO.jpg)
View original content with
multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-hold-third-quarter-2017-financial-results-conference-call-and-webcast-on-thursday-november-9th-300545979.html
SOURCE AcelRx Pharmaceuticals, Inc.